MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment (MARIA)
-
- STATUS
- Recruiting
-
- End date
- Dec 23, 2026
-
- participants needed
- 1000
-
- sponsor
- Invitae Corporation
Summary
This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients.
Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.
Description
This study involves collection of tumor tissue (from a standard biopsy and/or surgery) as well as blood samples over time in order to allow the creation of a Personalized Cancer Monitoring (PCM) assay. Additional blood samples are taken throughout the patient's treatment and follow-up period.
At minimum, each participant will submit one blood sample when they begin participation in the research study. Participants will be asked to submit follow up samples several times per year, with the exact frequency varying by stage and type of cancer. In general, participants will not be asked to come into the clinic more frequently than their already needed clinic visits.
If the cancer-specific mutations identified by the PCM are detected in the blood samples provided as part of the study, this may would suggests that residual cancer may be present. This is an observational study comparing MRD results to standard of care methods and collecting provider and patient perspectives. Physicians will be informed of all PCM results in the form of a clinical report. Physicians are not asked to base treatment decisions on these results
Details
| Condition | Cancer, Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer |
|---|---|
| Treatment | Personalized Cancer Monitoring (PCM) |
| Clinical Study Identifier | NCT05219734 |
| Sponsor | Invitae Corporation |
| Last Modified on | 23 March 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer